Mutual of America Capital Management’s Pacific Biosciences PACB Stock Holding History

Mutual of America Capital Management’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-111,798	Closed	-$1.02M	–	1635
2022 Q1	$1.02M	Sell	111,798 -4,861	-4%	-$56K	0.01%	1054
2021 Q4	$2.39M	Sell	116,659 -1,088	-0.9%	-$26.3K	0.02%	916
2021 Q3	$3.01M	Sell	117,747 -1,696	-1%	-$50.2K	0.03%	781
2021 Q2	$4.18M	Sell	119,443 -5,144	-4%	-$150K	0.04%	632
2021 Q1	$4.15M	Sell	124,587 -134,168	-52%	-$4.7M	0.04%	623
2020 Q4	$6.71M	Sell	258,755 -157,124	-38%	-$2.67M	0.08%	323
2020 Q3	$4.1M	Sell	415,879 -12,705	-3%	-$73.1K	0.05%	459
2020 Q2	$1.48M	Buy	428,584 +70,502	+20%	+$240K	0.02%	943
2020 Q1	$1.1M	Buy	358,082 +45,740	+15%	+$187K	0.02%	954
2019 Q4	$1.6M	Buy	312,342 +106,979	+52%	+$544K	0.02%	997
2019 Q3	$1.06M	Hold	205,363	–	–	0.01%	1055
2019 Q2	$1.24M	Sell	205,363 -114,012	-36%	-$799K	0.02%	1043
2019 Q1	$2.31M	Sell	319,375 -741	-0.2%	-$5.36K	0.03%	802
2018 Q4	$2.37M	Sell	320,116 -149,620	-32%	-$948K	0.04%	716
2018 Q3	$2.54M	Sell	469,736 -35,546	-7%	-$153K	0.04%	786
2018 Q2	$1.79M	Sell	505,282 -3,042	-0.6%	-$8.44K	0.03%	937
2018 Q1	$1.04M	Sell	508,324 -2,148	-0.4%	-$5.58K	0.02%	1069
2017 Q4	$1.35M	Buy	510,472 +28,384	+6%	+$99.4K	0.02%	1025
2017 Q3	$2.53M	Buy	482,088 +13,181	+3%	+$56.7K	0.04%	732
2017 Q2	$1.67M	Buy	468,907 +3,970	+0.9%	+$16K	0.03%	908
2017 Q1	$2.4M	Sell	464,937 -181,182	-28%	-$887K	0.04%	717
2016 Q4	$2.46M	Buy	646,119 +77,903	+14%	+$566K	0.05%	682
2016 Q3	$5.09M	Buy	568,216 +109,948	+24%	+$919K	0.1%	263
2016 Q2	$3.22M	Buy	458,268 +35,753	+8%	+$327K	0.07%	453
2016 Q1	$3.59M	Buy	422,515 +100,660	+31%	+$990K	0.08%	364
2015 Q4	$4.23M	Buy	321,855 +74,529	+30%	+$669K	0.09%	276
2015 Q3	$905K	Sell	247,326 -186,549	-43%	-$912K	0.02%	1005
2015 Q2	$2.5M	Hold	433,875	–	–	0.05%	591
2015 Q1	$2.53M	Buy	433,875 +5,412	+1%	+$37.3K	0.06%	589
2014 Q4	$3.36M	Buy	428,463 +12,653	+3%	+$81K	0.08%	417
2014 Q3	$2.04M	Buy	+415,810	New	+$2.17M	0.05%	649

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Mutual of America Capital Management's PACB Position: Q2 2022 in Review

Mutual of America Capital Management sold out of Pacific Biosciences (PACB) in Q2 2022, closing a stake of 111,798 shares — an estimated $1.02M sold.

Mutual of America Capital Management first reported a position in PACB in Q3 2014 and held it in 31 quarters. The position peaked at $6.71M in Q4 2020. 229 funds tracked by Wall St. Rank hold PACB as of Q2 2022.

Mutual of America Capital Management reported no remaining Pacific Biosciences position as of Q2 2022 after selling out during the quarter.
Mutual of America Capital Management sold 111,798 Pacific Biosciences shares in Q2 2022, an estimated $1.02M.
Mutual of America Capital Management first reported a position in Pacific Biosciences in Q3 2014 and held it in 31 quarters.
Mutual of America Capital Management's Pacific Biosciences position peaked at $6.71M in Q4 2020.
229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2022.

Based on Mutual of America Capital Management's 13F filing for Q2 2022, filed 10 Aug 2022.